Tweet
Pharma Marketletter
July 11, 2007 Wednesday
Generex announces Armenian Oral-lyn deal
USA-based Generex Biotechnology, a specialist in drug delivery for
metabolic diseases, has entered into an exclusive agreement with the
Armenian Development Agency and Canada Armenia Trading House which
covers the licensing and distribution of its oral insulin spray
product Oral-lyn. Specifically, the deal relates to the
commercialization of the drug in the Republic of Armenia, Georgia and
the Republic of Kazakhstan.
Under the terms of the accord, the ADA and CATH will bear the costs
associated with the procurement of governmental approvals for the
drug, including any clinical and regulatory expenses which are
incurred. Further details of the deal were not provided.
Anna Gluskin, Generex' president, said that the company hopes that
its product would soon be available to the estimated one million
people in the region that suffer from diabetes and its complications.
She added that the firm would continue to seek additional
international approvals for the product, as Phase III trials in
Europe, Canada and the USA are ongoing.
July 11, 2007 Wednesday
Generex announces Armenian Oral-lyn deal
USA-based Generex Biotechnology, a specialist in drug delivery for
metabolic diseases, has entered into an exclusive agreement with the
Armenian Development Agency and Canada Armenia Trading House which
covers the licensing and distribution of its oral insulin spray
product Oral-lyn. Specifically, the deal relates to the
commercialization of the drug in the Republic of Armenia, Georgia and
the Republic of Kazakhstan.
Under the terms of the accord, the ADA and CATH will bear the costs
associated with the procurement of governmental approvals for the
drug, including any clinical and regulatory expenses which are
incurred. Further details of the deal were not provided.
Anna Gluskin, Generex' president, said that the company hopes that
its product would soon be available to the estimated one million
people in the region that suffer from diabetes and its complications.
She added that the firm would continue to seek additional
international approvals for the product, as Phase III trials in
Europe, Canada and the USA are ongoing.